

Jean-Philip Piquemal

Sorbonne Université, Laboratoire de Chimie Théorique (LCT), UMR 7616 CNRS,
Tour 12-13, 4^{ème} étage, 4 place Jussieu, 75252 Paris Cedex, France. Tel: +33 1 44 27 25 04

E-mail : jean-philip.piquemal@sorbonne-universite.fr; Homepage: <http://piquemalresearch.com>;

X (formerly Twitter): [@jppiquem](https://twitter.com/jppiquem) ;

LinkedIn: [@jppiquem](https://www.linkedin.com/in/jppiquem)

Scientific career and education

Present situation	- Director and Distinguished Professor, Laboratoire de Chimie Théorique SU/CNRS - Principal Investigator ERC Synergy: project EMC ²
2023 - present	Distinguished Professor (EXceptional class, PREX-2, CNU 31), SU
2019 - present	Director, Laboratoire de Chimie Théorique (LCT), UMR 7616 SU/CNRS
2019 - present	Team leader, EMC2 research group at LCT (5 researchers), SU/CNRS
2015 - present	Adjunct Research Professor (Biomedical Engineering), UT Austin (USA)
2019 - 2023	Member, PRACE (Partnership for Advanced Computing in Europe) steering committee
2019 - 2023	Distinguished Professor (EXceptional class, PREX-1, CNU 31), SU
2016 - 2021	Member, Institut de France (junior research chair 2016-2021)
2016 - 2019	Full Professor (First class, PR1, CNU 31), SU
2012 - 2019	Team leader, MC2 interdisciplinary project team ("Maths-Chimie"), ISCD, SU
2012 - 2018	Director, Institut Parisien de Chimie Physique et Théorique, FR 2622, SU/CNRS
2012 - 2018	Team leader: research axis 2 at LCT (8 permanent researchers)
2011 - 2016	Full Professor (Second class, PR2), UPMC
2009 - 2011	Maître de Conférences - HDR (Associate Professor), UPMC
2009	Research Habilitation (HDR), UPMC, Paris 6
2006 - 2009	Maître de Conférences (Assistant Professor), UPMC
2004 - 2006	NIH Visiting Fellow, NIEHS, NC, USA. Group of Thomas A. Darden.
2001 - 2004	Ph.D. Thesis (allocataire-moniteur) in Theoretical Chemistry, UPMC
2000 - 2001	Diplôme d'Etude Approfondie (DEA, Master 2) in Theoretical Chemistry, UPMC
1998 - 2000	Licence (L3) & Master 1 (Maîtrise) in Chemistry (major: Physical Chemistry), UPEC

Affiliations: SU=Sorbonne Université; UPMC=Université Pierre et Marie Curie (Paris 6); NIEHS=National Institute of Environmental Health Sciences; UPEC=Université Paris-Est Créteil (Paris 12); CNRS=Centre National de la Recherche Scientifique; UT=University of Texas; IUF=Institut Universitaire de France.

Selected honors and funding

2024	i-Démo grant (French national innovation grant), 2025-2029
2024	Elected Councilor of the International Society of Quantum Biology and Pharmacology
2022	HPC Innovation Excellence Award
2022	H2020 Innovative Training Networks (ITN), Co-PI of the PHYMOL project
2022	Nominated as part of the 100 french innovators of the year by Le Point newsmagazine
2022	Fellow of the Royal Society of Chemistry (FRSC)
2021	EIC Accelerator (European Innovation Council innovation grant)
2020	i-Lab 2020 (French national innovation grant)
2019	ERC Synergy: Extreme-Scale Mathematics for Computational Chemistry, 2019-26
2018	Atos - Joseph Fourier Prize in High-Performance Computing (1 st prize)
2018	France-Berkeley Research fund.
2016	Junior member (research chair 2016-2021), Institut Universitaire de France
2013	CNRS PICS collaborative international fund (with UT Austin)
2012	Emergence-UPMC fund.
2011	Wiley -International Journal of Quantum Chemistry - Young Investigator Award
2008	France-Canada Excellence Research Fund (2008-2010).
2004	National Institute of Health (NIH) Visiting Fellowship award (2004-2006)

Scientific Production and Editorial Activities

- Publications: 200 (h-index: 57, citations > 12000, source Google Scholar)
- Development of the Tinker simulation package (Tinker-HP/Tinker) <https://tinker-hp.org>
- Editor: Results in Chemistry (Elsevier); Editorial Boards: International Journal of Quantum Chemistry (Wiley); Frontiers in Chemistry (Frontiers); LiveCoMS (Univ. Colorado)

Professional affiliations: Société Chimique de France, Royal Society of Chemistry, American Chemical Society, Association for Computing Machinery, Biophysical Society, ISQBP, Sigma Xi.

Industry: Co-founder (2020) and CSO of Qubit Pharmaceuticals, 2020-present (Paris, France).